According to the report by Expert Market Research (EMR), the Global Graft Versus Host Disease Treatment Market Size is projected to grow at a CAGR of 8.50% between 2023 and 2028. Aided by the growing prevalence of diseases requiring transplantation and the rapid advancements in medical biotechnology, the market is expected to grow significantly by 2028.
Graft versus host disease (GVHD) is a severe complication that can occur after a stem cell or bone marrow transplant, where donated cells attack the recipient’s body. It primarily affects the skin, liver, and gastrointestinal tract and can be acute or chronic, depending on the onset time. The treatment for GVHD usually involves immunosuppressive drugs to suppress the immune response and manage symptoms. Other therapies include steroids, photopheresis, and monoclonal antibodies.
Get a Free Sample Report with Table of Contents — https://www.expertmarketresearch.com/reports/graft-versus-host-disease-treatment-market/requestsample
The global graft versus host disease treatment market growth is primarily driven by the increasing prevalence of diseases like leukaemia, lymphoma, and multiple myeloma, requiring allogenic hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation (BMT). As transplantation procedures rise, so does the risk of GVHD, thereby increasing the demand for effective treatment options.
Furthermore, rapid advancements in medical biotechnology significantly contribute to the graft versus host disease treatment market expansion. The development of newer immunosuppressive agents and monoclonal antibodies has revolutionised GVHD treatment, offering better disease control and improving patient outcomes. The emergence of cellular therapies, like mesenchymal stem cells (MSCs) and regulatory T cells (Tregs), has opened new avenues for GVHD treatment, further fuelling market growth.
The global focus on personalised medicine is also impacting the graft versus host disease treatment market demand. Advancements in genomics and proteomics are enabling the development of tailored therapies based on individual patient profiles, improving treatment efficacy and reducing side effects. This shift towards personalised treatment is expected to provide a substantial boost to the GVHD treatment market.
Healthcare infrastructure improvement and increased healthcare spending, particularly in developed countries, are also supporting the graft versus host disease treatment market development. With better access to healthcare facilities and rising awareness about early diagnosis and treatment, the demand for GVHD treatment is set to increase.
Graft Versus Host Disease Treatment Market Segmentation
The market can be divided based on type, treatment, distribution channel, and region.
Read Full Report with Table of Contents — https://www.expertmarketresearch.com/reports/graft-versus-host-disease-treatment-market
Market Breakup by Type
- Acute Graft Versus Host Disease (aGvHD)
- Chronic Graft Versus Host Disease (cGvHD)
Market Breakup by Treatment
- mTOR Inhibitors
- TNFα Inhibitors
- SOT Therapies
- Stem Cell Treatments
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
The EMR report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global graft versus host disease treatment companies. Some of the major key players explored in the report by Expert Market Research are as follows:
- Incyte Corporation
- Mesoblast Ltd
- AbbVie Inc.
- Bristol Myers Squibb